-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang Fourth Pharmaceutical has won multiple prestigious awards on China’s most influential list in the pharmaceutical industry.
Category:
Time：2022-12-10
Recently, the Pharmaceutical Industry Chamber of the All-China Federation of Industry and Commerce released its 2021 list of the most influential companies in the pharmaceutical industry. In this highly acclaimed industry ranking, Shijiazhuang No.4 Pharmaceutical Co., Ltd. ranked 36th on the “Top 100 Chinese Pharmaceutical Manufacturers 2021” list and was also honored with the titles of “Law-Abiding and Integrity-Focused Enterprise in China’s Pharmaceutical Industry” and “Pioneer Enterprise in Independent Innovation in China’s Pharmaceutical Industry.”
Recently, the Pharmaceutical Industry Chamber of the All-China Federation of Industry and Commerce released its 2021 list of the most influential companies in the pharmaceutical industry. In this highly acclaimed industry ranking, Shijiazhuang No.4 Pharmaceutical Co., Ltd. ranked 36th on the “Top 100 Chinese Pharmaceutical Manufacturers 2021” list and was also honored with the titles of “Law-Abiding and Integrity-Focused Enterprise in China’s Pharmaceutical Industry” and “Pioneer Enterprise in Independent Innovation in China’s Pharmaceutical Industry.”
Since last year, Shijiazhuang No.4 Pharmaceutical has seized development opportunities and strengthened its sense of responsibility. Guided by the goal of smoothing the dual circulation of domestic and international markets, the company has leveraged its comparative advantages to build competitive strengths. The pace of transformation and upgrading has accelerated, industrial structure continues to optimize, and the development model has shifted from scale-driven to innovation-driven, presenting a rapid and stable growth trajectory. The company has achieved remarkable economic and social benefits and has consistently delivered impressive performance results. Su Xuejun, Chairman of Shijiazhuang No.4 Pharmaceutical, stated that the company will further extend, supplement, and strengthen its industrial chain. It will actively integrate its own development resources—including raw materials, talent, technology, and capital—by aligning the industrial chain with the innovation chain and deploying the innovation chain around the industrial chain. The company is committed to achieving new breakthroughs in overall scale, product structure, and development quality, and accelerating its move toward the mid-to-high end of the value chain.
It is reported that the “China Pharmaceutical Industry’s Most Influential List” selection event, organized by the Pharmaceutical Industry Chamber of the All-China Federation of Industry and Commerce, has been successfully held for nine consecutive sessions. The event aims to promote industry development and enable the winning enterprises and individuals to maximize their influence and make their voices heard most powerfully. With its comprehensive coverage of the entire industry chain, strong representativeness, and high level of participation, this event has become a prestigious and authoritative brand initiative in China’s pharmaceutical industry.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license